CN117561254A - 用于肺癌治疗的嘧啶基氨基苯 - Google Patents

用于肺癌治疗的嘧啶基氨基苯 Download PDF

Info

Publication number
CN117561254A
CN117561254A CN202280031627.6A CN202280031627A CN117561254A CN 117561254 A CN117561254 A CN 117561254A CN 202280031627 A CN202280031627 A CN 202280031627A CN 117561254 A CN117561254 A CN 117561254A
Authority
CN
China
Prior art keywords
amino
methyl
compound
ethyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280031627.6A
Other languages
English (en)
Chinese (zh)
Inventor
段茂盛
原帅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Puhe Pharmaceutical Technology Co ltd
Original Assignee
Suzhou Puhe Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Puhe Pharmaceutical Technology Co ltd filed Critical Suzhou Puhe Pharmaceutical Technology Co ltd
Publication of CN117561254A publication Critical patent/CN117561254A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280031627.6A 2021-04-30 2022-05-02 用于肺癌治疗的嘧啶基氨基苯 Pending CN117561254A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/091463 2021-04-30
CN2021091463 2021-04-30
PCT/CN2022/090836 WO2022228578A1 (en) 2021-04-30 2022-05-02 Pyrimidinylaminobenzenes for lung cancer treatment

Publications (1)

Publication Number Publication Date
CN117561254A true CN117561254A (zh) 2024-02-13

Family

ID=83847794

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280031627.6A Pending CN117561254A (zh) 2021-04-30 2022-05-02 用于肺癌治疗的嘧啶基氨基苯

Country Status (6)

Country Link
US (1) US20240226101A1 (https=)
EP (1) EP4330256A4 (https=)
JP (1) JP2024516430A (https=)
KR (1) KR20240027583A (https=)
CN (1) CN117561254A (https=)
WO (1) WO2022228578A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024094064A1 (en) * 2022-11-02 2024-05-10 Suzhou Puhe Biopharma Co., Ltd Pyrimidinylaminobenzenes for treating lung cancer with distant metastasis
CN116098873A (zh) * 2023-03-08 2023-05-12 苏州浦合医药科技有限公司 一种药物制剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761544B (zh) * 2014-01-03 2019-03-15 北京轩义医药科技有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
CN105085489B (zh) * 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
CN106279160B (zh) * 2016-03-18 2017-09-26 海南越康生物医药有限公司 N‑苯基‑2‑氨基嘧啶类化合物制备方法和用途
MX383920B (es) * 2016-05-26 2025-03-14 Recurium Ip Holdings Llc Compuestos inhibidores de egfr.
EP3585389A4 (en) * 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS
JP7028900B2 (ja) * 2017-06-13 2022-03-02 ベイジン アダマドル バイオテクノロジー リミテッド ライアビリティ カンパニー アミノピリミジン化合物、その調製方法、およびその使用
EP3641818A1 (en) * 2017-06-23 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for preventing or treating cancer resistance to egfr inhibition
CN111093645A (zh) * 2017-07-05 2020-05-01 Cs制药技术有限公司 Egfr酪氨酸激酶的临床上重要的突变体的选择性抑制剂
CN107266437B (zh) * 2017-07-19 2019-08-30 海南越康生物医药有限公司 N-苯基-2-氨基嘧啶类化合物的晶型、盐型及其制备方法
JP2021513517A (ja) * 2018-02-12 2021-05-27 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 非小細胞肺がんの治療に使用するためのオシメルチニブ
CN111588710B (zh) * 2019-02-21 2023-06-20 浙江大学 一种针对egfr耐药突变c797s的联用药物及用途
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物

Also Published As

Publication number Publication date
WO2022228578A1 (en) 2022-11-03
KR20240027583A (ko) 2024-03-04
EP4330256A1 (en) 2024-03-06
EP4330256A4 (en) 2025-03-05
US20240226101A1 (en) 2024-07-11
JP2024516430A (ja) 2024-04-15

Similar Documents

Publication Publication Date Title
TW202515564A (zh) 戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
TWI866977B (zh) 吡唑化合物之非吸濕性結晶鹽及其醫藥組合物及用途
US20250177334A1 (en) Pharmaceutical Compositions Comprising Phenylsulfonamides, and Their Therapeutic Applications
CN117561254A (zh) 用于肺癌治疗的嘧啶基氨基苯
US10988442B2 (en) Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use
US20150342942A1 (en) Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1h)-pyridone
KR20250006167A (ko) Cdk 억제제, 약제학적 조성물 및 이의 치료 용도
WO2024094064A1 (en) Pyrimidinylaminobenzenes for treating lung cancer with distant metastasis
US20240197713A1 (en) Lfa-1 antagonists for treating inflammatory bowel diesease
WO2024104422A1 (en) Phosphorus-containing compounds for treating inflammatory bowel diesease
CA3042055C (en) Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use
CN120535478A (zh) 脂质化合物、脂质纳米颗粒和药物组合物
WO2026080552A1 (en) Deoxycytidine kinase inhibitors for treating inflammatory bowel diseases
WO2023023474A1 (en) Tr-beta modulators, pharmaceutical compositions, and therapeutic applications
WO2010112091A1 (en) Compounds for treatment of duchenne muscular dystrophy
HK40007061B (en) Pharmaceutical compositions of treating cardiovascular diseases, preparation thereof, and method of using the same
HK40007061A (en) Pharmaceutical compositions of treating cardiovascular diseases, preparation thereof, and method of using the same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination